Literature DB >> 22595235

Merlin, a multi-suppressor from cell membrane to the nucleus.

Lu Zhou1, C Oliver Hanemann.   

Abstract

Recent evidence suggests that the neurofibromatosis type 2 (NF2) gene encoded protein merlin suppresses mitogenic signalling not only at the cell membrane but also in the nucleus. At the membrane, merlin inhibits signalling by integrins and tyrosine receptor kinases (RTKs) and the activation of downstream pathways, including the Ras/Raf/MEK/ERK, FAK/Src, PI3K/AKT, Rac/PAK/JNK, mTORC1, and Wnt/β-catenin pathways. In the nucleus, merlin suppresses the E3 ubiquitin ligase CRL4(DCAF1) to inhibit proliferation. Gene expression analysis suggested that CRL4(DCAF1) could also regulate the expression of integrins and RTKs. In this review, we explore the links between merlin function at the membrane and in the nucleus, and discuss the potential of targeting the master regulator CRL4 (DCAF1) to treat NF2 and other merlin-deficient tumours.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22595235     DOI: 10.1016/j.febslet.2012.03.016

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  23 in total

1.  A deletion causing NF2 exon 9 skipping is associated with familial autosomal dominant intramedullary ependymoma.

Authors:  Ilyess Zemmoura; Patrick Vourc'h; Agathe Paubel; Béatrice Parfait; Joëlle Cohen; Frédéric Bilan; Alain Kitzis; Cécilia Rousselot; Fabrice Parker; Patrick François; Christian R Andres
Journal:  Neuro Oncol       Date:  2013-12-18       Impact factor: 12.300

2.  Cellular prion protein (PrPC) in the development of Merlin-deficient tumours.

Authors:  L Provenzano; Y Ryan; D A Hilton; J Lyons-Rimmer; F Dave; E A Maze; C L Adams; R Rigby-Jones; S Ammoun; C O Hanemann
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

3.  Merlin status regulates p75(NTR) expression and apoptotic signaling in Schwann cells following nerve injury.

Authors:  Iram Ahmad; Augusta Fernando; Richard Gurgel; J Jason Clark; Linjing Xu; Marlan R Hansen
Journal:  Neurobiol Dis       Date:  2015-06-06       Impact factor: 5.996

4.  Re-evaluation of cytostatic therapies for meningiomas in vitro.

Authors:  Annette Wilisch-Neumann; Doreen Pachow; Maren Wallesch; Astrid Petermann; Frank D Böhmer; Elmar Kirches; Christian Mawrin
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-11       Impact factor: 4.553

Review 5.  Neurofibromatosis-related tumors: emerging biology and therapies.

Authors:  Matthias A Karajannis; Rosalie E Ferner
Journal:  Curr Opin Pediatr       Date:  2015-02       Impact factor: 2.856

6.  Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas.

Authors:  Maurits de Vries; Inge Briaire-de Bruijn; Anne-Marie Cleton-Jansen; Martijn J A Malessy; Andel G L van der Mey; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2012-12-08       Impact factor: 4.064

Review 7.  Merlin, the NF2 gene product.

Authors:  Nives Pećina-Šlaus
Journal:  Pathol Oncol Res       Date:  2013-05-12       Impact factor: 3.201

Review 8.  Meningioma.

Authors:  Ali-Reza Fathi; Ulrich Roelcke
Journal:  Curr Neurol Neurosci Rep       Date:  2013-04       Impact factor: 5.081

9.  p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB.

Authors:  Iram Ahmad; Wei Ying Yue; Augusta Fernando; J Jason Clark; Erika A Woodson; Marlan R Hansen
Journal:  Glia       Date:  2014-06-26       Impact factor: 7.452

10.  The hippo pathway is activated and is a causal mechanism for adipogenesis in arrhythmogenic cardiomyopathy.

Authors:  Suet Nee Chen; Priyatansh Gurha; Raffaella Lombardi; Alessandra Ruggiero; James T Willerson; A J Marian
Journal:  Circ Res       Date:  2013-11-25       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.